CCF Celebrates Major Milestone in Connecting Patients and Caregivers to Mentorship Program

September 2023, Vol 4, No 3

The Cholangiocarcinoma Foundation (CCF) is celebrating the 1000th mentor–mentee match and 6 years of their mentoring program, CholangioConnect. CCF has developed unique resources to help patients and caregivers navigate their healthcare journeys.

Cholangiocarcinoma (CCA) is a type of cancer that forms in the bile ducts of the liver. With approximately 10,000 cases of CCA being diagnosed in the United States each year, bile duct cancer is the second most common primary liver cancer in the world. It is often diagnosed at advanced stages when treatment is minimally effective, emphasizing the urgent need for novel therapies and strong patient support.

CCF’s CholangioConnect creates personalized connections that enable one-on-one support among CCA patients, survivors, and caregivers. New members are connected to a mentor who has personal experience with the disease and can offer support at any stage in the CCA management journey. The CholangioConnect program has expanded to meet the needs of patients and caregivers and is offering mentorship to those living in the United States and 31 other countries.

Karla Boyden, CCA patient/survivor, and Carla Anderson, CCA patient/survivor

“Our CholangioConnect staff have a keen sense of what our patients and caregivers need and match them with mentors who have walked in their shoes,” said Stacie Lindsey, CCF’s Founder and CEO. “We celebrate the 1000-strong connections made over the past 6 years while also focusing on innovative research that leads to new treatments and a cure, and strengthening the support network that improves the quality of life of patients.”

Patty Maxin, caregiver to her husband Mike Lu who passed away in 2015, became CholangioConnect’s first program manager. She has also served as a patient and research advocate and on the CCF Board of Directors. “Patients and caregivers give selflessly in order to walk alongside others who are in need of a helping hand, an ear, or just the confirmation that they are not in this alone,” Maxin said of the CholangioConnect mentors.

CholangioConnect mentors receive training and support materials and are assigned mentees who they support through phone calls, email, and participation in virtual support groups.

Mentoring services are tailored to fit the needs of the mentees and time and availability of the mentors. “Mentors of CholangioConnect understand by experience, the fear and loneliness of this diagnosis, as all volunteers have a personal relationship with bile duct cancer,” Maxin said.

“Profound bonds are forged, and mentorships give way to lasting friendships that are sometimes only possible when both parties emotionally respond to a common adversity. They show us courage and the opportunity to witness humanity at its best.”

Rob Howard provided care to his father who was battling CCA. Howard was paired with a mentor through CholangioConnect, and now he provides the same support to other caregivers. “The truth is simple: The CholangioConnect program fundamentally changed how I navigated the uncertain and scary world of my dad’s diagnosis,” Howard said. “My initial phone call with my mentor lasted over an hour, and I went from feeling scared and alone, to feeling informed, hopeful, and better equipped to face the uncertain times ahead for my dad and our family.” Completing 1000 connections between mentors and mentees means 1000 patients and caregivers have received strong emotional support, tailored resources, and a support network. It also underscores the need for life-saving treatments.

In celebrating 6 successful years of CholangioConnect, CCF is expanding the program to serve even more people in need of support. To learn more about CholangioConnect and to be assigned or become a mentor, visit

Related Items

10th Annual Cholangiocarcinoma Foundation Conference: International Collaboration, Patient Connections, Industry Updates
June 2023, Vol 4, No 2
Cancer investigators and clinicians from around the world connected with patients, caregivers, and industry officials at the foundation’s conference in Salt Lake City, UT.
CCF Welcomes a New Standard of Care
By Allison Deragon, Cholangiocarcinoma Foundation
March 2023, Vol 4, No 1
CCF discusses the approval of durvalumab for cholangiocarcinoma, a milestone that, it is hoped, will open doors for other innovative immunotherapy combinations.
Think Tank of Multidisciplinary Experts Develop Proposals to Improve Outcomes in Patients with CCA
December 2022, Vol 3, No 4
A group of 29 expert scientists and clinicians from the world’s leading academic institutions developed potentially transformative project proposals while gathered in Las Vegas for a 2-day meeting called Cure Cholangiocarcinoma Think Tank (C2T2).
International Cholangiocarcinoma Patient Registry Accelerates and Supports CCA Research
September 2022, Vol 3, No 3
The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA).
Clinical Trial Enrollment Challenges for Patients with Cholangiocarcinoma
By Reham Abdel-Wahab, MD, PhD; Samantha Pear
June/July 2022, Vol 3, No 2
There is a desperate need for patients with CCA to gain access to clinical trials to help improve survival.
The Cholangiocarcinoma Foundation’s Patient Advocacy Initiatives
March 2022, Vol 3, No 1
At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on February 22-25, Melinda Bachini, Director of Advocacy of CCF, provided an update about the foundation’s advocacy and patient support initiatives. The goal of the CCF’s advocacy group is to provide educational and emotional support for the cholangiocarcinoma (CCA) community of patients and caregivers, and to empower them with the knowledge and guidance needed to self-advocate.
New ICD-11 Codes for Cholangiocarcinoma
December 2021, Vol 2, No 4
The Cholangiocarcinoma Foundation (CCF) is encouraging healthcare professionals to support the adoption of the new International Classification of Diseases, 11th Revision (ICD-11), and its role in creating more robust epidemiological data for cholangio­carcinoma (CCA).
The International Cholangiocarcinoma Research Network: Educational and Research Achievements
By Reham Abdel-Wahab, MD, PhD
December 2021, Vol 2, No 4
In 2015, the Cholangiocarcinoma Foundation (CCF) launched the International Cholangiocarcinoma Research Network (ICRN). This network is a global collaborative of clinicians, researchers, and scientists from leading academic medical centers and research institutions working together to improve the prevention, early detection, treatment, and prognosis of cholangiocarcinoma (CCA).
Navigating Compassionate Use Options for Your Patients with Cholangiocarcinoma
By Melinda Bachini
September/October 2021, Vol 2, No 3
I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA.
A Watershed Moment for the Cholangiocarcinoma Community
By Stacie C. Lindsey
June/July 2021, Vol 2, No 2
In an article published last year in CCA News, I shared the Cholangiocarcinoma Foundation (CCF)’s philosophy on taking risks and leveraging collaboration over competition. The CCF was nearing its 15th anniversary, and the FDA had recently approved pemigatinib (Pemazyre), the first targeted therapy approved for cholangiocarcinoma (CCA).

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: